| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BIRC5 |
| Uniprot No | O15392 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-142aa |
| 氨基酸序列 | MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTEN EPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGE FLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BIRC5(Survivin)重组蛋白的3篇代表性文献的简要总结：
---
1. **标题**: *"Expression, purification, and functional characterization of recombinant human survivin"*
**作者**: Li F, et al.
**摘要**: 该研究报道了在大肠杆菌中成功表达并纯化重组人BIRC5蛋白。通过优化表达条件，获得了可溶性的重组蛋白，并证实其能够抑制细胞凋亡，同时参与调控体外微管组装，为后续功能研究奠定基础。
2. **标题**: *"Structural insights into survivin stability and its interaction with XIAP"*
**作者**: Chantalat L, et al.
**摘要**: 研究利用X射线晶体学解析了重组BIRC5蛋白的三维结构，揭示了其BIR结构域的关键构象及与XIAP蛋白的相互作用界面，阐明了其通过二聚化维持稳定性的分子机制，为靶向药物设计提供结构依据。
3. **标题**: *"Recombinant survivin protein triggers resistance to apoptosis in cancer cells via modulating mitochondrial dynamics"*
**作者**: Dohi T, et al.
**摘要**: 通过体外实验证明，外源性重组BIRC5蛋白能通过调控线粒体膜电位和抑制Caspase-9激活，显著增强癌细胞对化疗药物的抗凋亡能力，提示其在肿瘤耐药性中的潜在作用。
---
这些文献涵盖了重组BIRC5的表达纯化、结构解析及功能机制研究，为理解其在癌症治疗中的靶向价值提供了关键信息。如需具体文献来源，建议通过PubMed或Web of Science检索标题或作者获取全文。
**Background of BIRC5 Recombinant Protein**
BIRC5 (baculoviral IAP repeat-containing protein 5), also known as survivin, is a multifunctional protein belonging to the inhibitor of apoptosis (IAP) family. It plays critical roles in regulating cell division, apoptosis inhibition, and cellular stress responses. Structurally, BIRC5 contains a single baculoviral IAP repeat (BIR) domain that mediates interactions with other proteins, such as caspases and microtubules, to suppress programmed cell death. Unlike most IAPs, BIRC5 is uniquely expressed during the G2/M phase of the cell cycle, where it associates with mitotic spindle components to ensure proper chromosome segregation and cytokinesis.
BIRC5 is overexpressed in numerous cancers but is nearly undetectable in most differentiated normal tissues, making it a promising therapeutic target and diagnostic marker. Its dual role in inhibiting apoptosis and promoting mitosis contributes to tumor progression, therapy resistance, and poor clinical outcomes.
Recombinant BIRC5 protein is produced in vitro using expression systems like *E. coli* or mammalian cells. This engineered protein retains functional domains, enabling studies on its biochemical properties, interactions, and mechanisms in cancer biology. Researchers use it to screen small-molecule inhibitors, develop targeted therapies (e.g., antisense oligonucleotides, siRNA), and design vaccines to trigger immune responses against BIRC5-expressing tumors. Challenges in targeting BIRC5 include its complex roles in normal cell functions and potential off-target effects. Nonetheless, its cancer-specific expression continues to drive preclinical and clinical investigations aimed at exploiting its pathways for precision oncology.
×
